Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346603 · ClinicalTrials.gov registry record
Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs
A clinical trial, sponsored by Olive View-UCLA Education & Research Institute.
- Completed
- Registry status
- 801
- Enrollment target
NCT03346603: Completed study, sponsored by Olive View-UCLA Education & Research Institute.
NCT03346603 is a clinical trial that has completed, run by Olive View-UCLA Education & Research Institute. The registered enrollment target is 801 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03346603 has completed, sponsored by Olive View-UCLA Education & Research Institute.
- COMPLETED
- Registry status
- 801 participants
- Enrollment target
Study Summary
Between 2013-2014, our study network of U.S. emergency departments, EMERGEncy ID NET, found that the rate of fluoroquinolone-resistant E. coli was 11.7% among all patients, 6.3% in uncomplicated and 19.9% in complicated. ESBL-producing Enterobacteriaceae were found in 7.7% of all cases, 2.6% in uncomplicated and 12.2% in complicated. More recently, Enterobactericeae and gram-negative non fermenting bacteria have started to show resistance to carbapenems (CREs and CR-NF). Patients hospitalized with UTI and urosepsis represent a higher risk population for infections due to multi-drug resistant bacteria and experience serious adverse outcomes, including death. EMERGEncy ID NET will conduct a study to determine the prevalence of ESBL-producing, CREs and CR-NFs among this high risk population of patients admitted for UTI from U.S. emergency departments.
Interventions
- OTHER urine culture and susceptibility testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 801 participants |
| Start Date | 2018-02-08 |
| Est. Completion | 2020-12-31 |
What the finished NCT03346603 record still lists
NCT03346603 is an observational study that tracks outcomes without assigning an intervention. The registered 801 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which urine culture and susceptibility testing is the first listed.
NCT03346603 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03346603 about?
NCT03346603 is a clinical study titled "Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs". Between 2013-2014, our study network of U.S. emergency departments, EMERGEncy ID NET, found that the rate of fluoroquinolone-resistant E. coli was 11.7% among all patients, 6.3% in uncomplicated and 19.9% in complicated. ESBL-producing Enterobacteriaceae were found in 7.7% of all cases, 2.6% in unco...
What is the current status of trial NCT03346603?
This trial is currently completed. The enrollment target is 801 participants. The study started on 2018-02-08. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03346603?
The interventions under investigation include: urine culture and susceptibility testing (OTHER).
Who is sponsoring clinical trial NCT03346603?
This trial is sponsored by Olive View-UCLA Education & Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI